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Abstract
Rationale Epidemiological studies have demonstrated a
comorbidity of smoking with depression and anxiety,
particularly during adolescence. However, few animal
studies have considered possible synergistic interactions
between nicotine and other tobacco smoke constituents,
such as monoamine oxidase (MAO) inhibitors, in the
regulation of mood.
Objectives The aim of the study was to test the hypothesis
that nicotine combined with the irreversible MAO inhibitor,
tranylcypromine, will differentially affect depression- and
anxiety-related behaviors in adolescent and adult rats.
Methods Nicotine (0, 0.05, 0.2 mg/kg, s.c.) and tranylcy-
promine (3 mg/kg, i.p.) were tested separately, or together,
on male rats aged postnatal days 30 and 68, in three mood-
related behavioral tests: forced swim test (FST), elevated
plus maze (EPM), and open field.
Results Nicotine (0.2 mg/kg) in adults significantly de-
creased floating time in the FST and increased time spent in
the open arm of the EPM, with no change in locomotor
activity. Tranylcypromine pretreatment combined with
nicotine (0.2 mg/kg) significantly increased locomotor
activity and time spent in the center of the open field.
Whereas nicotine alone had no significant effect on
adolescents, it significantly increased locomotor activity
and decreased floating time in the FST when combined
with tranylcypromine pretreatment.
Conclusions There is an age-dependent effect of nicotine,
alone and in combination with MAO inhibition, on mood-
related behaviors. Whereas nicotine alone induces mood
improvement in adults, it has no effect on adolescents.
Nicotine combined with tranylcypromine has unique, age-
dependent effects. Thus, experimental studies of smoking
should consider both age and other tobacco constituents,
such as MAO inhibitors, as critical factors.
Keywords Nicotine.Tranylcypromine.Depression.
Anxiety.Locomotoractivity
Abbreviations
EPM Elevated plus maze
FST Forced swim test
MAO Monoamine oxidase
P Postnatal day
Introduction
Tobacco is one of the most abused reinforcing agents in
humans (Balfour et al. 2000). Beside tobacco-induced
physical dependence, most smokers report that key motives
for smoking include alleviation of negative moods such as
anxiety, sadness, and stress (Spielberger and Jacobs 1982;
Shiffman 1993). There is considerable evidence that
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people with major anxiety disorders than in the general
population (26%; Lasser et al. 2000; Morris et al. 2006).
The link between psychiatric disorders and tobacco
smoking seems even stronger in adolescents as young
adults are at high risk for vulnerability to both serious
mental illness and cigarette smoking (Laviola et al. 2003;
Breslau et al. 2004; Slawecki et al. 2005; Snyder 2006).
Teenagers with depressive disorders are 4.6 times more
prone to smoking than teenagers without a depressive
disorder (Fergusson et al. 1996). These observations have
led several authors to hypothesize that tobacco compounds
may improve mood state (Khantzian 1997; Poirier et al.
2002; Upadhyaya et al. 2002).
In order to assess this hypothesis, several studies have
tested nicotine on animal models of depression and anxiety
in behavioral paradigms that assess mood-related behavior
(File et al. 1998; Tizabi et al. 1999; Irvine et al. 1999;
Ouagazzal et al. 1999; Cheeta et al. 2000; Vazquez-Palacios
et al. 2004, 2005). Whereas nicotine may affect mood
(Salin-Pascual and Drucker-Colin 1998), other tobacco
constituents may also be involved in this phenomenon. To
date, over 4,000 compounds have been identified in
tobacco smoke (Report 1989), some of which are known
to inhibit monoamine oxidase (MAO). MAO is a mito-
chondrial enzyme responsible for the breakdown of mono-
amines. Two forms of the enzyme, MAO A and B, are
synthesized by two distinct genes (Shih 2004). Chronic
smoking has been shown to irreversibly inhibit MAO by
40% to 50% (Fowler et al. 1996a, b, 2003), which may play
an important role to elevate mood and may explain the high
prevalence of smokers among people with major depression
(Fowler et al. 1996a).
The aim of the present study was to test the hypothesis
that two components of tobacco smoke, nicotine and MAO
inhibitors, can affect mood-related behaviors when tested
separately or in combination. Our protocol was designed so
that behavioral tests with nicotine were done when MAO
activity is inhibited, as in smokers. Tranylcypromine is an
irreversible MAO A and B inhibitor sometimes used as an
antidepressant in humans. In the present study, tranylcy-
promine was used acutely to reduce MAO activity,
although our aim was not to cause antidepressant effects.
It was injected 20 h prior to nicotine administration to avoid
itsimmediatemonoamine-releasingeffectthatcouldinfluence
behavioral responses measured soon after injection
(Baker et al. 1992). Under these conditions, a tranylcy-
promine (3 mg/kg, i.p.) pretreatment decreases MAO
activity by 70% to 80% in the rat brain and induces a
significant increase of nicotine-induced reward (Villégier
et al. 2007). This protocol, which has been developed in
our laboratory to model the effects of smoking, has the
advantage of combining two effects of tobacco smoke,
MAO inhibition and nicotine administration. We believe
that this treatment more accurately models cigarette
smoking than nicotine administration alone.
Our aim was to determine whether MAO inhibition
influenced the effects of nicotine on mood-related behaviors,
as well as its rewarding properties. To do so, three paradigms
were used to assess emotional behaviors: (1) the forced
swim test (FST) to measure the floating time commonly
considered as “behavioral despair”, a depression-related
behavior, (2) the elevated plus maze (EPM) to assess
anxiety-related behavior, and (3) the open field to test
inhibition of exploratory behavior, measured using the
percentage of time spent in the central arena and total
locomotion (Prut and Belzung 2003). As adolescence is
described as a key period for initiation of tobacco
consumption, we tested rats at two different ages,
postnatal days (P) 30 and 68, to examine whether nicotine
and MAO inhibitor effects on depressive- and anxiety-like
behavior would vary according to age.
Materials and methods
Animals
Male Sprague–Dawley rats were obtained from Charles
River at P22 and P60. Animals were housed in groups of
four and maintained on a 12-h light/dark cycle (lights on at
07:00 a.m.) with food and water available ad libitum. Rats
were allowed at least 1 week of acclimation to the
vivarium environment after their arrival, before any treat-
ments began. All tests were performed during the light part
of the light–dark cycle. The animals used in this study
were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited vivar-
ium maintained by University of California (UC) Irvine
University Laboratory Animal Resources personnel. All
experimental procedures were performed in compliance
with National Institutes of Health (NIH) Guide for Care
and Use of Laboratory Animals (NIH no. 85–23, rev.
1985) and approved by the UC Irvine Institutional Animal
Care and Use Committee. All efforts were made to
minimize animal suffering and to reduce the number of
animals used.
Forced swim test
Adolescent and adult rats were subjected to the FST (n=
113), according to the method previously described (Porsolt
et al. 1977). Rats were weighed and handled for 3 days,
receiving saline injections on the third day. On day 4
(pretest), each rat, aged P29 or P67, was placed in a glass
cylinder (54 cm in height and 24 cm in diameter) filled with
594 Psychopharmacology (2010) 208:593–601water to a depth of 40 cm (23–25°C) and allowed to swim
for 15 min. Animals were then removed from the cylinder,
dried, and returned to their home cages. Pretreatment
injections of tranylcypromine (3 mg/kg, i.p.) or saline
(1.5 ml/kg, i.p.) were given 20 h prior to the FST, and the
following day, injections of nicotine (0.05, 0.2 mg/kg, s.c.)
or saline (0.75 ml/kg, s.c.) were given 10 min prior to the
FST. On day 5 (test), rats were allowed to swim in the glass
cylinders for 5 min. All test sessions were recorded by a
video camera from the top of the cylinder. Duration of rat’s
floating, climbing, and swimming in the water was scored
from videotapes by a trained observer who was blinded to
the experimental conditions. Floating was defined as the
state in which rats were judged to be making only the
movements necessary to keep their head above the surface.
Elevated plus maze
Adolescent and adult rats were subjected to a test in the
EPM (n=98), according to a method previously described
(Daniels et al. 2004). Rats were weighed and handled for
3 days, receiving saline injections (1.5 ml/kg, i.p.) on the
third day. Injections of tranylcypromine (3 mg/kg, i.p.) and
saline (1.5 ml/kg, i.p.) pretreatments were given 20 h prior
to the test, with injections of nicotine (0.05, 0.2 mg/kg, s.c.)
or saline (0.75 ml/kg, s.c.) being given 10 min prior. On
day 4 (test), adolescent and adult rats were subjected to
behavioral assessment in an EPM. The EPM consists in a
plus-shaped acryl maze with two opposite open arms
(50 cm in length and 10 cm in width) and two opposite
closed arms (50 cm in length, 10 cm width, and 31 cm in
height), extending out from a central platform (10×10 cm).
The whole apparatus was elevated 50 cm above the floor.
Each rat was placed in the center of the maze and then
allowed to explore the open or closed arms of the maze for
5 min. The time spent in the different arms was recorded.
Two paws had to be inside the entrance line to each arm,
which signaled the start of the time spent in the specific
arm, and then the end time was recorded when all four
paws were outside the line again. The maze was cleaned
with 70% ethanol after each test to prevent influences of
previously tested rat.
Ambulatory activity and center time
Adolescent and adult rats were subjected to a test in the
open field (n=62), according to the method previously
described (Prut and Belzung 2003). Rats were weighed and
handled for 3 days, receiving saline injections (1.5 ml/kg,
i.p.) on the third day. Injections of the tranylcypromine
(3 mg/kg, i.p.) and saline (1.5 ml/kg, i.p.) pretreatments
were scheduled 20 h prior to the test, and injections of
nicotine (0.2 mg/kg, s.c.) or saline (0.75 ml/kg, s.c.) were
performed immediately prior to the test. On day 4 (test),
adolescent and adult rats were placed into the middle of a
well-illuminated locomotion box immediately after drug
injection. Locomotor activity was measured for 30 min
using an open-field activity system measuring 43.2×43.2×
30.5 cm (MED Associates, Inc., St. Albans, VT, USA).
Horizontal movement was monitored by 16 evenly spaced
infrared beams located along two adjacent sides of the
chamber. The time spent in the center area of the apparatus,
considered as a model of stress-induced inhibition of
exploratory behavior, was monitored simultaneously.
Materials
Drugs (−)-Nicotine hydrogen tartrate and tranylcypromine
hydrochloride were purchased from Sigma-Aldrich. Doses
are expressed as salts, except for nicotine which is
expressed as base. The products were dissolved in saline
(NaCl, 0.9%) with pH adjusted to 7.4 with NaOH.
Statistics
Results presented are means±SEM of data obtained with
seven to 11 animals per group. Data were analyzed using
four-way ANOVA (for pretreatment×treatment×age×
time interaction), three-way ANOVA (for pretreatment×
treatment×age interaction, pretreatment×treatment×time
interaction or treatment×age×time interaction with repeated
measures on time), two-way ANOVA (for pretreatment×
treatment interaction, treatment×age interaction or treat-
ment×time interaction with repeated measures on time), and
one-way ANOVA (for pretreatment, treatment, age, and time
effect). Significant effects were tested separately with
ANOVAs and Bonferroni- or Dunnett-corrected post hoc
comparisons. Time was treated as within-subject factors, and
pharmacological treatments and age were analyzed as
between-subjects factors. All statistical analyses were per-
formed using SYSTAT 10 statistical software. Statistical
significance was set at p<0.05.
Results
Forced swim test
The effect of tranylcypromine pretreatment on time spent
floating, climbing, and swimming in the FST, following
nicotine (0, 0.05, and 0.2 mg/kg), is shown in Fig. 1.
Statistical analysis of floating showed significant effects of
tranylcypromine dose (F1, 102=4.6778, p=0.0329), age
(F1, 102=8.6648, p=0.0040), and a nicotine dose×age
interaction (F2, 102=4.0007, p=0.0212). For adolescents,
Psychopharmacology (2010) 208:593–601 595there was a significant effect of tranylcypromine dose
(F1, 47=10.3438, p=0.0024), nicotine dose (F2, 47=3.2376,
p=0.0482), and a tranylcypromine×nicotine dose interac-
tion (F2, 47=5.8740, p=0.0053). Post hoc tests showed that
floating was significantly decreased following nicotine
(0.2 mg/kg) in tranylcypromine-pretreated as compared to
saline-pretreated adolescents (p=0.0002; Fig. 1). In adults,
there was a significant effect of nicotine dose (F2, 57=3.87,
p=0.027). Post hoc tests showed that floating time in adults
treated with nicotine (0.2 mg/kg) was significantly reduced
when compared to the saline adult group (p=0.03).
Comparison of floating behavior in saline-pretreated rats
only showed a significant age effect (F1, 53=13.5119, p=
0.0006) and age×nicotine dose interaction (F2, 53=7.2051,
p=0.0017). Post hoc Bonferroni corrected t tests showed
that floating in adult following nicotine (0.2 mg/kg) was
significantly reduced when compared to the same dose in
adolescents (p=0.007; Fig. 1).
Statisticalanalysisofclimbingbehaviorshowedsignificant
effects ofage (F1, 102=12.3444, p=0.0007) and nicotine dose
(F2, 102=3.3781, p=0.0380), while no significant tranylcy-
promine effect was found (p>0.0712; Fig. 1). Whereas
nicotine had no significant effect on climbing behavior in
adolescents, there was a significant effect of nicotine
dose (F2, 54=3.124, p=0.05) in adults. Post hoc analysis
showed that climbing was significantly higher in saline-
pretreated adults following nicotine (0.2 mg/kg) injection
as compared to saline injection (p=0.019). Climbing
induced by nicotine (0.2 mg/kg) in saline-pretreated adults
was significantly higher than in saline-pretreated adolescents
(p=0.02; Fig. 1).
Statistical analysis of swimming showed significant
tranylcypromine dose effect (F1, 102=4.5219, p=0.0359)
and a nicotine dose×age interaction (F2, 102=6.6149,
p=0.002). In adolescents, significant effects of tranylcy-
promine dose (F1, 47=5.6764, p=0.0213), nicotine dose
(F2, 47=4.4925, p=0.0164), and a tranylcypromine×
nicotine dose interaction (F2, 47=3.4228, p=0.0409) were
found in adolescents, whereas none of these effects were
significant in adults (p>0.0960). Post hoc Dunnett-corrected
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Fig. 1 Nicotine and MAO inhi-
bition effects on FST in adoles-
cent and adult rats. Adult and
adolescent rats were tested in the
FST 20 h following tranylcy-
promine (3 mg/kg, i.p.) or saline
(1.5 ml/kg, i.p.) pretreatment
and 10 min following saline or
nicotine (0.05 or 0.2 mg/kg, s.c.)
treatment. A synergistic action
of tranylcypromine pretreatment
and nicotine (0.2 mg/kg)
treatment induced an
antidepressant-like effect in
adolescent. *p<0.05 versus
saline–saline; **p<0.01 versus
saline–nicotine 0.05 mg/kg, and
tranylcypromine–nicotine
0.05 mg/kg; ***p<0.001 versus
saline–nicotine 0.2 mg/kg; #p<
0.05 versus saline–nicotine
0.05 mg/kg and
tranylcypromine–nicotine
0.05 mg/kg; ##p<0.01 versus
saline–nicotine 0.2 mg/kg.
In adults, nicotine 0.2 mg/kg
i.p. induces a significant
antidepressant-like effect.
*p<0.05; **p<0.01 versus
saline–saline. A significant age
difference was obtained. ##p<
0.05 versus corresponding ado-
lescent group. n=8 per group
596 Psychopharmacology (2010) 208:593–601t test showed that nicotine (0.2 mg/kg) significantly
increased swimming in tranylcypromine-pretreated adoles-
cents as compared to saline pretreated (p=0.0070; Fig. 1).
Elevated plus maze
The effect of nicotine (0, 0.05, and 0.2 mg/kg) on the
percentage of time spent in the open arm of the EPM is
presented Fig. 2. As no significant tranylcypromine dose
effect was found (F1, 95=0.0835, p=0.7733), data from
tranylcypromine- and saline-pretreated groups were com-
bined. ANOVA showed an overall nicotine dose effect
(F2, 101=4.6955, p=0.0112) and a significant age effect
(F1, 101=4.3854, p=0.0388). Nicotine dose effect was
significant in adults (F2, 46=4.4446, p=0.0172) but not
in adolescents (F2, 55=0.8780, p=0.4214). Post hoc
adjusted Dunnett comparison showed that, in adults,
nicotine (0.2 mg/kg) significantly increased the time spent
in the open arm when compared to saline and nicotine
0.05 mg/kg (p<0.0493). Furthermore, the time spent in
the open arm following nicotine (0.05 mg/kg) was
significantly higher in adolescent than in adults (p=
0.0007; Fig. 2). No effect of nicotine and tranylcypromine
was found on the percentage of open arm entries, total arm
entries, and total arm time (p>0.5; Table 1).
Ambulatory distance and center time
The effect of nicotine (0.2 mg/kg), tranylcypromine (3 mg/kg),
and their combination on ambulatory distance and percentage
of time spent in the center of the open field is presented in
Fig. 3a, b. For ambulatory distance, ANOVA showed a
significant effect of nicotine dose (F1, 53=16.1765, p=
0.0002), tranylcypromine dose (F1, 53=18.1271, p=0.0001),
age (F1, 53=8.5497, p=0.0051), and age×nicotine dose
interaction (F1, 53=10.8377, p=0.0018; Fig. 3a). Moreover,
a significant effect of time (F2, 106=155.4711, p=0.0000) and
interactions of time×age (F2, 106=4.6865, p=0.0112), time×
nicotine dose×age (F2, 106=16.3704, p=0.0000), and time×
nicotine dose×tranylcypromine dose×age (F2, 106=4.0482,
p=0.0202) were found.
In adolescents, ANOVA showed a significant time effect
(F2, 56=92.9693, p=0.0000) and time×nicotine dose
interaction (F2, 56=5.5801, p=0.0062). Post hoc Dunnett-
corrected t tests showed that ambulatory distance following
nicotine injection in tranylcypromine-pretreated adolescents
was significantly higher than following saline injection at
t=10 min (p=0.0005) and t=20 min (p=0.0149). In adults,
a significant effect of time (F2, 50=67.2110, p=0.000) and
interactions of time×nicotine dose (F2, 50=12.6741, p=
0.000) and time×nicotine dose×tranylcypromine dose
(F2, 50=3.7292, p=0.0309) were found. Post hoc Dunnett-
corrected t tests showed that ambulatory distance following
saline injection in tranylcypromine-pretreated adults was
significantly higher than the three other groups at t=10 min
(p<0.0311) and than following saline injection in the
saline-pretreated group at t=20 min (p=0.0258). Moreover,
ambulatory distance following nicotine injection in
tranylcypromine-pretreated adults was significantly higher
than following saline injection in the saline-pretreated
group at t=20 min (p=0.0258) and than the three other
groups at t=30 min (p<0.0024).
Percentage of time spent in the central part of the arena
is considered as a measure of stress-induced inhibition of
exploration behavior. ANOVA showed a significant effect
of age (F1, 52=138.3624, p=0.000), tranylcypromine dose
(F1, 52=8.3402, p=0.0056), and a tranylcypromine dose×
age interaction (F1, 52=8.5177, p=0.0052; Fig. 3b). More-
over, a significant effect of time (F2, 104=3.3992, p=
0.0372) and interactions of time×nicotine dose (F2, 104=
6.0764, p=0.0032), time×age (F2, 104=3.4760, p=0.0346),
time×nicotine dose×tranylcypromine dose×age (F2, 104=
4.9435, p=0.0089), time×nicotine dose×tranylcypromine
dose (F2, 104=4.8922, p=0.0093), and time×nicotine
dose×age (F2, 104=6.0628, p=0.0032) were found. No
significant drug effects were observed in adolescents
whereas, in adults, there were significant effects of time
(F2, 50=3.1991, p=0.0493), tranylcypromine dose (F1, 25=
7.8505, p=0.0097), and interactions of time×nicotine dose
(F2, 50=5.6504, p=0.0061) and time×nicotine dose×
tranylcypromine dose (F2, 50=4.5783, p=0.0149; Fig. 3b).
Post hoc Dunnett-corrected t tests showed that the time
spent in the center space following nicotine injection in
tranylcypromine-pretreated adults was significantly higher
than the three other groups at t=30 min (p<0.0223;
Fig. 3b).
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Fig. 2 Effect of nicotine and MAO inhibition on the percentage
time spent in the open arm of the EPM. Adult and adolescent rats
were tested in the EPM 20 h following tranylcypromine (3 mg/kg,
i.p.) or saline (1.5 ml/kg, i.p.) and 10 min following nicotine (0.05,
0.2 mg/kg, s.c.) or saline (0.75 ml/kg, s.c.). As no effect of MAO
inhibition was found, data from saline- and tranylcypromine-
pretreated groups were combined. *p<0.05 versus adult saline and
adult nicotine 0.05 mg/kg; ###p<0.001 versus corresponding
adolescent. n=10–22 per group
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Whereas tobacco smoke contains over 4,000 constituents
(Report 1989; Lewis et al. 2007), most experimental
analyses of smoking with animal models examine the
effects of nicotine alone. Given the prominent inhibition of
MAO activity in the brains and periphery of smokers
(Fowler et al. 1996a, b, 2003), the present study was
designed to assess possible synergistic interactions between
nicotine and MAO inhibition on depression- and anxiety-
related behaviors in adolescent and adult rats. Since the
irreversible MAO inhibitor in tobacco smoke has not yet
been structurally characterized (Lewis et al. 2007), we used
tranylcypromine (3 mg/kg), a clinical irreversible inhibitor
of MAO-A and MAO-B, to inhibit MAO activity prior to
nicotine treatment. Pretreatment with this MAO inhibitor
has previously been shown to increase the reinforcing
effects of nicotine in both adult and adolescent rats
(Villégier et al. 2007). Given prior observations that
tranylcypromine has acute effects that are unrelated to
MAO inhibition (Baker et al. 1992; Villégier et al. 2007),
animals were pretreated with the MAO inhibitor 20 h prior
to behavioral testing. We have previously shown that
MAO-A and MAO-B activity remains inhibited by approx-
imately 70% and 85%, respectively, 20 h after tranylcypro-
mine pretreatment (Villégier et al. 2007). This is somewhat
greater than the 40% to 50% decrease seen in the brains of
smokers (Fowler et al. 1996a, b).
Assessment of mood-related behaviors in animals is
complex and open to multiple interpretations (Cryan et al.
Age Tranyl–nico dose (mg/kg) % Open arm entries Total arm entries Total arm time
Adult sal–sal 38.13±6.349 19.73±5.466 172.6±6.384
Adolescent sal–sal 42.91±6.001 17.44±1.692 165.8±9.451
Adult sal–nico0.05 29.48±5.975 14±1.673 171±21
Adolescent sal–nico0.05 41.31±5.921 19.89±1.359 171.3±11.44
Adult sal–nico0.2 47.69±11.26 19.63±4.242 175.8±13.78
Adolescent sal–nico0.2 36.64±2.707 21±0.9888 158.6±8.308
Adult tranyl3–sal 41.24±3.886 15.5±1.098 171.2±9.013
Adolescent tranyl3–sal 34.78±5.762 18.56±1.345 153±13.16
Adult tranyl3–nico0.05 26.27±4.255 20±1.581 171.6±4.027
Adolescent tranyl3–nico0.05 42.24±2.915 23.78±1.906 184.6±8.499
Adult tranyl3–nico0.02 41.25±8.212 26.6±7.218 161.1±12.89
Adolescent tranyl3–nico0.02 50.18±6.567 22.75±1.28 170.4±8.951
Table 1 Effects of nicotine and
MAO inhibition in the EPM
test in adolescent and adult rats
Results are expressed as means±
SEM. n=10–22 per group
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Fig. 3 Effect of nicotine and
MAO inhibition on a ambulatory
distance and b center time. Adult
and adolescent rats were tested in
the open field 20 h following
tranylcypromine (3 mg/kg, i.p.)
or saline (1.5 ml/kg, i.p.) and
10 min following nicotine
(0.2 mg/kg, s.c.) or saline
(0.75 ml/kg, s.c.). Ambulatory
distance was significantly
i n c r e a s e di nb o t ha d u l t sa n d
adolescents by tranylcypromine
and nicotine. *p<0.05; **p<0.01
versus corresponding saline.
Time spent in the center area of
the open field was significantly
increased in adults following
nicotine and tranylcypromine
pretreatment. *p<0.05 versus the
other treatments. n=8 per group
598 Psychopharmacology (2010) 208:593–6012002a; Ramos 2008). We have used two common tests of
anxiety-related behavior, the open field test and the EPM.
These tests have been shown to measure different aspects of
emotionality (reviewed by Ramos 2008). The FST has been
widely used to measure depressive-like behavioral states in
animals (Overstreet 1993; Lucki 1997; Cryan et al. 2002a).
Although these tests have been critiqued for showing
immediate responses to antidepressant drugs, when clinical
findings require longer exposure, it has been shown that
more potent effects are obtained in this test when drug
exposure is chronic (Cryan et al. 2005). For the present
study, we chose not to do long-term exposure to nicotine
and tranylcypromine since this drug combination has been
shown to increase in psychostimulant efficacy with repeated
drug exposure (Villégier et al. 2003).
Behavioral effects of nicotine alone
Nicotine alone had no significant behavioral effect in
adolescent rats. In contrast, nicotine (0.2 mg/kg) signifi-
cantly decreased floating time and increased climbing time
in the FST in adult rats. This phenomenon was dissociated
from any stimulant effect on locomotor activity. Floating
response, or immobility, remains a widely used tool to
evaluate “behavioral despair”. A decrease in immobility
and increased climbing, as was seen in this study, is
associated with increased noradrenergic activity in the
ventral bundle pathway from brainstem nuclei (Cryan et
al. 2002a, b). This behavioral response may result from a
direct nicotine activation of brainstem noradrenergic nuclei,
which we have previously shown to express nicotinic
receptor subunit mRNAs in an age-dependent manner
(O’Leary et al. 2008). Our behavioral findings are also
consistent with prior studies in adult rats in which the same
dose (0.2 mg/kg) and a higher dose (0.4 mg/kg) of nicotine
yielded comparable results, i.e., an antidepressant-like
effect of nicotine that was dissociable from its effects on
locomotor activity (Tizabi et al. 1999; Vazquez-Palacios et
al. 2004, 2005). Future studies should examine whether
these effects are mediated by noradrenergic activation.
In parallel, we report that nicotine (0.2 mg/kg) increases
the time spent in the open arm of the EPM by adult rats. As
EPM is an established animal model of anxiety-like
behavior (Hogg 1996), used to evaluate panic and general-
ized anxiety disorder (Cheeta et al. 2000), the present data
indicate an alleviation of an anxiety-like state. A lower dose
of nicotine (0.05 mg/kg) induced a trend toward decreased
time spent in the open arm which, although not significantly
different from saline-treated adults, was significantly
different from adolescents treated with the same nicotine
dose. Nicotine has been previously reported to present
bimodal effects on anxiety, showing both anxiolytic and
anxiogenic effects in animal tests (File et al. 1998;I r v i n e
et al. 1999; Ouagazzal et al. 1999;C h e e t ae ta l .2000;
Kenny et al. 2000). The response to nicotine is dependent
on experimental conditions, including the period of drug
exposure (withdrawal, acute or chronic administration,
p r e n a t a l ;S l a w e c k ie ta l .2005), drug doses, and the
behavioral paradigm used to assess anxiety-related behavior
(Tucci et al. 2003; Ouagazzal et al. 1999; Marco et al. 2005).
As shown by the present study, nicotine’se f f e c to na n x i e t yi s
also dependent on the model used to measure anxiety. We
used the open field to measure both anxiety-like behaviors
and locomotor activity (Prut and Belzung 2003). Because
the animal is separated from its social group and that the
arena is very large relative to the animal’s breeding or
natural environment, the open field is considered to
measure reaction to a stressful event. In both adults and
adolescents, nicotine had no effect on ambulatory distance
or stress-induced inhibition of exploratory behavior. This
finding is different from that found previously, where an
intravenous injection of nicotine increased locomotor
activity in juveniles but decreased it in adults, while
center time was increased at both ages (Cao et al. 2007).
Nicotine doses and route of administration may explain
these differing results.
Behavioral effects of nicotine and tranylcypromine
Tranylcypromine alone had no effect on either depression-
or anxiety-like behavior in adult and adolescent rats, when
given 20 h prior to testing. In contrast, tranylcypromine
pretreatment given 1 h prior to FST significantly decreased
floating and increased climbing in adult rats (data not
shown), consistent with prior literature findings with MAO
inhibitors (Cryan et al. 2005; Shimazu et al. 2005). A
significant stimulant effect of tranylcypromine pretreatment
on locomotion was seen in adult rats, but not adolescents,
during open-field testing. This may be due to a differential
sensitivity to MAO inhibition of response to novelty at the
two different ages, with adults being more sensitive than
juvenile rats.
Whereas several prior studies have assessed nicotine
effects on depression- and anxiety-related behavior (File et
al. 1998; Irvine et al. 1999; Ouagazzal et al. 1999; Tizabi et
al. 1999; Cheeta et al. 2000; Kenny et al. 2000; Vazquez-
Palacios et al. 2004, 2005), the present is the first to
combine nicotine and MAO inhibition. Whereas nicotine
had no effect on saline-pretreated adolescents, it signifi-
cantly reduced floating and increased swimming in the FST
when combined with tranylcypromine pretreatment. This is
consistent with an antidepressant-like effect of this drug
combination, mediated via activation of serotonergic
mechanisms (Cryan et al. 2002a). Since the drug combina-
tion did enhance locomotor activity in adolescent animals, a
spurious psychostimulant effect cannot be completely ruled
Psychopharmacology (2010) 208:593–601 599out as an explanation for these findings. However, this
seems unlikely since the psychostimulant effect of tranyl-
cypromine alone in adults was not associated with
behavioral changes in the FST. Another explanation is a
reduced aversive response to an explicitly negative envi-
ronment, as has been shown previously in adult rats (Vale
and Balfour 1989). Given the complexities of interpretation
of these data, further studies are warranted to determine
whether nicotine mitigates depressive behavior in adoles-
cents when combined with MAO inhibition. Possible
regulation of serotonergic systems should also be examined
as a mechanism underlying the enhanced swimming. Prior
studies have shown direct cholinergic modulation of
serotonergic cells in the dorsal raphe via nicotinic receptor
activation (Galindo-Charles et al. 2008). Nicotine has also
been reported to have complex effects on serotonergic
transmission in both juvenile and adult brain (Engberg et al.
2000; Li et al. 1998).
One other significant effect of the nicotine/tranylcypro-
mine combination was a significant increase in the
percentage time spent in the center of the open field by
adults. Although there was a corresponding increase in
locomotor activity, this is unlikely to underlie the increased
exploration of the center field since this did not occur at an
earlier time point when psychostimulant effects of tranyl-
cypromine alone were observed. Nor did increased center
time accompany the psychostimulant response to nicotine/
tranylcypromine combination seen in adolescents. These
data afford further support for a synergistic action between
nicotine and MAO inhibitors, as has been described
previously for self-administration and behavioral sensitiza-
tion (Villégier et al. 2003, 2005, 2007).
Conclusion
The present study shows that the effects of nicotine on
mood-related behaviors are highly dependent on age. These
findings are consistent with prior behavioral and neuro-
chemical studies showing substantial age differences in
response to nicotine (reviewed by Dwyer et al. 2009). We
now show that the effects of MAO inhibition are similarly
age dependent. In particular, adolescents treated with the
combination of nicotine and MAO inhibitor show an acute
psychostimulant response and decreased depressive-like
behavior, in contrast to adults. Such findings emphasize
the need to consider both age and the influence of other
tobacco smoke constituents when using animal models to
establish mechanisms underlying smoking behavior.
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